Pharvaris (PHVS) Stock Forecast & Price Target $31.41 +0.73 (+2.38%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$31.44 +0.02 (+0.08%) As of 10/23/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Analyst Forecasts Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Pharvaris - Analysts' Recommendations and Stock Price Forecast (2026) How MarketBeat Calculates Price Target and Consensus Rating Consensus Rating Moderate BuyBased on 15 Analyst RatingsSell1Hold0Buy14 Based on 15 Wall Street analysts who have issued ratings for Pharvaris in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 1 has given a sell rating, and 14 have given a buy rating for PHVS. Consensus Price Target $59.5389.54% Upside According to the 15 analysts' twelve-month price targets for Pharvaris, the average price target is $59.53. The highest price target for PHVS is $79.00, while the lowest price target for PHVS is $42.00. The average price target represents a forecasted upside of 89.54% from the current price of $31.41. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data. Get the Latest News and Ratings for PHVS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Pharvaris and its competitors. Sign Up View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHVS Analyst Ratings Over TimeTypeCurrent Forecast10/25/25 to 10/25/261 Month Ago9/25/25 to 9/25/263 Months Ago7/27/25 to 7/27/261 Year Ago10/25/24 to 10/25/25Strong Buy0 Strong Buy rating(s)0 Strong Buy rating(s)1 Strong Buy rating(s)0 Strong Buy rating(s)Buy14 Buy rating(s)13 Buy rating(s)10 Buy rating(s)5 Buy rating(s)Hold0 Hold rating(s)1 Hold rating(s)2 Hold rating(s)2 Hold rating(s)Sell1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)1 Sell rating(s)Consensus Price Target$59.53$59.87$50.08$37.17Forecasted Upside89.54% Upside86.97% Upside47.43% Upside61.66% UpsideConsensus RatingModerate BuyModerate BuyModerate BuyModerate Buy PHVS Analyst Recommendations By MonthAnalyst Ratings Chart DescriptionThe chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.Skip Chart & View Analyst Rating History PHVS Price Targets by MonthAverage Share Price and Price Target by Month Chart DescriptionThe chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table Pharvaris Stock vs. The CompetitionTypePharvarisHealthcare CompaniesBroader MarketConsensus Rating Score 2.87 2.32 2.53Consensus RatingModerate BuyHoldModerate BuyPredicted Upside89.54% Upside1,400.11% Upside16.92% UpsideNews Sentiment RatingPositive NewsSee Recent PHVS NewsNeutral NewsPositive News Recent Analyst Forecasts and Stock Ratings Most Recent from Each Brokerage All Show All Ratings Strong Buy Buy Hold Sell Rating Show All Upside > 100% Upside 50% - 100% Upside 20% - 50% Upside 10% - 20% Upside 0% - 10% Downside 0% - 10% Downside 10% - 20% Downside 20% - 50% Downside 50% - 100% Downside > 100% Upside/Downside All Actions Upgrades Downgrades Initiates Coverage Raises Target Lowers Target Reiterates Rating Action 10/25/2024 - 10/25/2026 Report Date Report Date From Report Date To 1M3M6MYTD1Y2Y3Y5Y More filters Fewer filters Done 0 Results Export DateBrokerageAnalystActionRatingPrice TargetReport Date Upside/DownsideDetails10/23/2026 Oppenheimer3 of 5 stars Reiterated RatingOutperform10/23/2026 Bank of America4 of 5 starsTazeen Ahmad4 of 5 starsUpgradeNeutral ➝ Buy$44.00+43.42%10/15/2026 Weiss Ratings3 of 5 stars Reiterated RatingSell (D-)10/6/2026 UBS GroupSubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$60.00+94.86%10/6/2026 HC WainwrightSubscribe to MarketBeat All Access to unlock brokerage rankingsPatrick R. TrucchioSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingBuy9/14/2026 Cantor FitzgeraldSubscribe to MarketBeat All Access to unlock brokerage rankingsSteven SeedhouseSubscribe to MarketBeat All Access to unlock analyst rankingsReiterated RatingOverweight$65.00+63.71%9/10/2026 GuggenheimSubscribe to MarketBeat All Access to unlock brokerage rankingsDebjit ChattopadhyaySubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetBuy$40.00 ➝ $44.00+16.59%9/9/2026 WedbushSubscribe to MarketBeat All Access to unlock brokerage rankingsLaura ChicoSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$42.00 ➝ $50.00+32.68%9/9/2026 Leerink PartnersSubscribe to MarketBeat All Access to unlock brokerage rankingsJoseph SchwartzSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$50.00 ➝ $65.00+72.49%9/9/2026 Rosenblatt SecuritiesSubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$60.00+59.96% Get the Latest News and Ratings for PHVS and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter. 9/9/2026 Morgan StanleySubscribe to MarketBeat All Access to unlock brokerage rankingsMaxwell SkorSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$46.00 ➝ $62.00+63.85%9/9/2026 Wells Fargo & CompanySubscribe to MarketBeat All Access to unlock brokerage rankingsYanan ZhuSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOverweight$55.00 ➝ $65.00+71.78%9/9/2026 CitigroupSubscribe to MarketBeat All Access to unlock brokerage rankings Reiterated RatingMarket Outperform9/9/2026 Royal Bank Of CanadaSubscribe to MarketBeat All Access to unlock brokerage rankingsNevin VargheseSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetOutperform$52.00 ➝ $62.00+65.03%9/9/2026 Citizens JmpSubscribe to MarketBeat All Access to unlock brokerage rankingsJonathan WollebenSubscribe to MarketBeat All Access to unlock analyst rankingsBoost TargetMarket Outperform$75.00 ➝ $79.00+108.77%8/14/2026 New Street ResearchSubscribe to MarketBeat All Access to unlock brokerage rankings Set Target$60.00+76.26%8/13/2026 HSBCSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeOverweight4/9/2026 Wolfe ResearchSubscribe to MarketBeat All Access to unlock brokerage rankingsAndy ChenSubscribe to MarketBeat All Access to unlock analyst rankingsInitiated CoverageOutperform$42.00+52.39%8/18/2025 Zacks ResearchSubscribe to MarketBeat All Access to unlock brokerage rankings UpgradeStrong Sell ➝ HoldAnalyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 04:39 PM ET. PHVS Forecast - Frequently Asked Questions What is Pharvaris' forecast for 2026? According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Pharvaris is $59.53, with a high forecast of $79.00 and a low forecast of $42.00. Should I buy or sell Pharvaris stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last year. There is currently 1 sell rating and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" PHVS shares. Does Pharvaris's stock price have much upside? According to analysts, Pharvaris's stock has a predicted upside of 89.54% based on their 12-month stock forecasts. Has Pharvaris been upgraded by Wall Street analysts recently? Over the previous 90 days, Pharvaris's stock had 2 upgrades by analysts. What analysts cover Pharvaris? Pharvaris has been rated by research analysts at Bank of America, Cantor Fitzgerald, Citigroup, Citizens Jmp, Guggenheim, HC Wainwright, HSBC, Leerink Partners, Morgan Stanley, New Street Research, Oppenheimer, Rosenblatt Securities, Royal Bank Of Canada, UBS Group, Wedbush, Weiss Ratings, and Wells Fargo & Company in the past 90 days. Do Wall Street analysts like Pharvaris more than its competitors? Analysts like Pharvaris more than other "healthcare" companies. The consensus rating for Pharvaris is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how PHVS compares to other companies. Stock Forecasts and Research Tools Related Companies CYTK Stock Forecast ABVX Stock Forecast IONS Stock Forecast PRAX Stock Forecast ALKS Stock Forecast IOVA Stock Forecast GRAL Stock Forecast KNSA Stock Forecast LGND Stock Forecast RYTM Stock Forecast Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Brokerages With Pharvaris RecommendationsOppenheimerBank of AmericaWeiss RatingsHC WainwrightUBS GroupCantor FitzgeraldGuggenheimCitigroupWedbushRoyal Bank Of CanadaMorgan StanleyWells Fargo & CompanyLeerink PartnersCitizens JmpRosenblatt Securities MarketBeat monitors more than a dozen sources for Pharvaris analyst ratings, with the most recent rating issued on 10/23/2026. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredWhy Gerardo Del Real says wait before buying uranium stocksGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharvaris N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharvaris With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.